WA-AWS
26.5.2020 09:02:08 CEST | Business Wire | Press release
Today, Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), and the German Bundesliga will debut the first two Bundesliga Match Facts powered by AWS during tonight’s highlight match at 18:30 CET featuring Borussia Dortmund vs. Bayern Muenchen on broadcast television in over 200 countries. The two new statistics, Average Positions and Expected Goals (xGoals), will give fans deeper insights into a team’s intended playing style based on real-time analysis performed of data captured from tracking players’ locations on the field, and the probability of a player scoring a goal. Germany’s top national football league will leverage AWS’s unmatched set of cloud services, including machine learning and analytics, to introduce additional advanced statistics in 2020 and upcoming seasons. AWS and the Bundesliga are the first to deliver this unique combination of real-time advanced statistics and game analyses to football (soccer) fans around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005205/en/
Bundesliga Match Facts are generated by gathering data from the live game video feeds that are streamed into AWS for analysis, and then provided back to broadcast viewers around the world in real-time as statistics. These statistics help audiences better understand things like the strategy involved in decision-making on the pitch and the probability of a goal for each shot. As of May 26, Average Positions will be available during future broadcasts of Bundesliga matches, while xGoals will be available during highlight matches.
A look at the two new Bundesliga Match Facts powered by AWS
Average Positions: Fans will now be able to see the positioning of a team’s players on the pitch and gain insight into the team’s intended playing style. Average Positions provides new insights based on analysis performed on data captured from tracking a player’s average location on the field, which is then displayed in real-time. This Bundesliga Match Fact allows viewers to identify the current momentum on the field and understand tactical changes. The new statistic will help pinpoint if a team is setting up in an attacking or defending style, pressing up the middle, or utilizing the wings. By displaying the average location and position of each player in real-time, Average Positions helps fans understand tactical changes as the game progresses.
xGoals : Using Amazon SageMaker, a fully managed service to build, train and deploy machine learning models, the Bundesliga can now assess the probability of a player scoring a goal when shooting from any position on the field. The goal probability is calculated in real-time for every shot to give viewers insight into the difficulty of a shot and the likelihood of a goal. To calculate the precision of xGoals, machine learning models were trained by analyzing 40,000 historical shots on goal in addition to an array of features derived from positional data, including distance to goal, angle to goal, player speed, number of defenders in line of shot, and goalkeeper coverage.
“We at Bundesliga are able to use this advanced technology from AWS, including statistics, analytics and machine learning, to interpret the data and deliver more in-depth insight and better understanding of the split-second decisions made on the pitch," said Andreas Heyden, Executive Vice President of Digital Innovations for the DFL Group. "The use of Bundesliga Match Facts enables viewers to gain a deeper insight into the key decisions in each match."
“AWS is helping the Bundesliga enhance the broadcast viewing experience by delivering deeper insights into the game that didn’t previously exist,” said Andy Isherwood, Vice President and Managing Director EMEA, AWS. “With AWS, Bundesliga is able to provide real-time statistics to predict future plays and outcomes. These two new statistics are just the beginning of what we’ll be able to deliver for football fans as we look forward to unlocking new ways to better educate, engage, and entertain viewers around the world.”
Football fans can follow all of the latest Bundesliga action, with Match Facts powered by AWS, on Bundesliga.com and via the official Facebook , Twitter , and Instagram channels.
About Amazon Web Services
For 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 76 Availability Zones (AZs) within 24 geographic regions, with announced plans for nine more Availability Zones and three more AWS Regions in Indonesia, Japan, and Spain. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com .
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews .
About the Bundesliga
The Bundesliga is the top professional association football league in Germany. The league was established in 1963 and comprises 18 teams which operate on a system of promotion and relegation with the Bundesliga 2. The Bundesliga is broadcast on television in over 200 countries and is operated by the DFL Deutsche Fußball Liga.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005205/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom